Richard Parkes
Pharmaceuticals and Biotechnology Equity Analyst at BNP Paribas Exane

Richard has conducted research and analysis of the pharmaceutical and biotechnology industries for close to 25 years in senior roles as an equity analyst at multiple investment banks, including BNP Paribas Exane, Deutsche Bank, Piper Jaffray and ING Financial Markets. During this time, he has developed an extensive knowledge of industry pipelines and an ability to critically appraise and value innovation.

He has subsequently been highly ranked in the Institutional Investor survey and been involved in initial public offerings for multiple biotechnology and pharmaceutical companies. Richard gained his Ph.D in Molecular Genetics from the Liverpool School of Tropical Medicines and subsequently conducted postdoctoral research in gene therapy at the Institute of Child Health, UCL, London.